Hetero receives DCGI marketing approval for generic Epclusa

Hetero, a Hyderabad-based leading generic pharmaceutical company and the world’s largest producer of anti-retroviral drugs, has received the approval from Drugs Controller General of India (DCGI) for the generic version of sofosbuvir+velpatasvir’ combination. The product will be marketed and distributed under the brand name ‘Velasof’ in India by Hetero Healthcare Ltd.hetero

Sofosbuvir+velpatasvir is a two-drug fixed dose combination product that contains 400mg of sofosbuvir and 100mg of velpatasvir in a single tablet. This fixed-dose combination is the generic version of Gilead’s brand Epclusa, approved by US FDA for the treatment of patients with chronic hepatitis C genotype 1 to 6.

This product will be launched under the non-exclusive licensing agreement with Gilead Sciences, Inc., which allows to manufacture and sell generic versions of its chronic hepatitis C medicines in 101 developing countries.

Don't be shellfish...Share on Facebook0Share on Google+0Share on LinkedIn0Share on StumbleUpon0Pin on Pinterest0Tweet about this on Twitter0
Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Most Popular

To Top